Navigation Links
Oncothyreon to receive milestone payment
Date:5/14/2008

uture prospects, this release contains statements that are forward looking, including statements related to payments Oncothyreon may expect to receive; the therapeutic and commercial potential of Stimuvax; future clinical development plans; the details of clinical trials; and the anticipated future size of the market for Stimuvax. These forward-looking statements represent Oncothyreon's intentions, plans, expectations and beliefs and are based on its management's experience and assessment of historical and future trends and the application of key assumptions relating to future events and circumstances.

Forward-looking statements involve risks and uncertainties, including risks and uncertainties related to Oncothyreon's business and the general economic environment. Many of these risks and uncertainties are beyond Oncothyreon's control. These risks, uncertainties and other factors could cause our actual results to differ materially from those projected in forward-looking statements. Risks, uncertainties, and assumptions include those predicting the timing, duration and results of clinical trials, the timing and results of regulatory reviews, the safety and efficacy of Stimuvax, and the possibility of future milestone and royalty payments. There can be no guarantee that the results of earlier trials will be predictive of either safety or efficacy in future trials. These and other risks and uncertainties are described in the reports and other documents filed by Oncothyreon Inc. with the SEC and/or Canadian regulatory authorities.

Although Oncothyreon believes that any forward-looking statements contained herein are reasonable, it can give no assurance that its expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For a detailed description of the risks and uncertainties associated with Oncothyreon, you are encouraged to review the official corporate documents filed by Oncothyreon I
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncothyreon Reports First Quarter 2008 Financial Results
2. Oncothyreon files investigational new drug application for PX-866 oncology compound
3. Data for Oncothyreons PX-12 and PX-866 presented at AACR Annual Meeting
4. Oncothyreon announces data from multiple small molecule programs to be presented at American Association of Cancer Research Annual Meeting
5. Oncothyreon announces effectiveness of shelf registration statement
6. Oncothyreon announces issuance of patent for PX-867
7. Oncothyreon to present at upcoming investment conferences
8. Oncothyreon reports full year and fourth quarter 2007 financial results
9. Oncothyreon announces March 10th webcast of fourth quarter and full year financial results conference call
10. Oncothyreons PX-478 is effective in preclinical model of human lung cancer
11. Oncothyreon launches new corporate website
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... ... June 30, 2015 , ... uBiome and OpenBiome Partner for ... of fecal microbiota transplantation in C. difficile patients. , SAN FRANCISCO, uBiome and ... fecal microbiota transplantation (FMT) as a treatment for Clostridium difficile infections (C. diff). ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... the federal government, announced in a paper published this week in the scientific ... problem with the diagnostic techniques currently used to detect the Ebola virus. Noblis ...
(Date:6/30/2015)... ... 2015 , ... Matrix Marketing Group, LLC , a leading provider of ... head up its account management department as vice president of client services. Amanda ... account management and delivery expertise to the growing Matrix Marketing Group team in Denver, ...
(Date:6/30/2015)... 30, 2015  Custom Computer Specialists, Inc. ("Custom"), a ... are silver sponsors of the Primary Care Development Corporation,s ... is lending their support of PCDC,s mission to expand ... Since its founding in 1993, PCDC has been a ...  PCDC has financed over 100 completed primary care projects, ...
Breaking Biology Technology:uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 2uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 3Noblis and Government Scientists Identify New Genomic Signatures of Ebola Using Whole Genomic Sequencing and Innovative BioVelocity Analytics Tool 2Noblis and Government Scientists Identify New Genomic Signatures of Ebola Using Whole Genomic Sequencing and Innovative BioVelocity Analytics Tool 3Noblis and Government Scientists Identify New Genomic Signatures of Ebola Using Whole Genomic Sequencing and Innovative BioVelocity Analytics Tool 4Matrix Marketing Group Expands Client Services Team 2Custom Computer Specialists Announces Sponsorship Of The Primary Care Development Corporation's Corporate Circle 2
... , Multiporator / Electroporator 2510 , , , , , , ... , Protocol No. 4308 915.503 04/2002 ... , , , , , , , ... , , Cell type , ...
... , , , Multiporator / Electroporator 2510 , , , , ... Transformation Protocol , Protocol No. 4308 915.501 04/2002 , ... , , , ... , Cell type , Bacteria, gram negative, ...
... , , , , Multiporator , , , , , ... Transfection Protocol , Protocol No. 4308 915.034 11/1999 , , ... , , Cell line , ... Transfection with , Plasmid pEGFP-N1 (in bidistilled H 2 O), ...
Cached Biology Technology:Azotobacter vinelandii 2Actinomyces viscosus 2A 20 2
(Date:6/30/2015)... , June 30, 2015 To bolster its efforts ... HYPR Corp. announced today the addition of two new team ... as board advisor and David Raviv will act ... underscore HYPR Corp.,s commitment to providing the most secure solutions ... Sirota co-founded Layer 7 Technologies, a provider of security ...
(Date:6/30/2015)... Genisphere announced Tom Bliss ... further develop Genisphere,s therapeutics capabilities and portfolio. Mr. Bliss ... much of the last 25 years in leadership positions ... Johnson & Johnson. Tom started his career in Investment ... Finance. He graduated from Dartmouth College with a BA ...
(Date:6/29/2015)... DUBLIN , June 24, 2015 ... the addition of the "Latin America Biomedical Sensors ... to their offering. The Latin America Biomedical ... at a CAGR of 2.04% over the period 2014-2020 ... that are adaptable to the genetic formulation of each ...
Breaking Biology News(10 mins):HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3Latin America Biomedical Sensors Market Report 2015-2020 2
... National Centers for Coastal Ocean Science and the Monterey ... first remote detection of a harmful algal species and ... recently reported in the June issue of Oceanography ... NOAA,s effort to monitor the type and toxicity of ...
... National Institutes of Health has awarded a five year $20 ... for Clinical and Translational Science. The grant is the ... rich intellectual breadth of the UIC campus and adds to ... campus," said Paula Allen-Meares, UIC chancellor. Translational research -- ...
... nothing on Rice University biologist Amy Dunham. In a newly ... primatology,s long-standing mysteries: Why are male and female lemurs the ... to be much larger than females. Size is an advantage ... mating with them, and evolutionary biologists have long wondered why ...
Cached Biology News:Scientists report first remote, underwater detection of harmful algae, toxins 2$20 million NIH grant to transform clinical research at UIC 2New theory on why male, female lemurs same size 2New theory on why male, female lemurs same size 3
Superior homology search software - in all the flavours of blast, with increased sensitivity and speed...
... mini Tray (3 per pack), 1. ... and blot processing.Automated staining of Coomassie ... and nucleic acid analysis.Prepares blots for ... detection.Programmable control of protocol, solution, volume, ...
75 x 25 mm; sterile, recommended for immunohistochemistry of cell lines growing in suspension, Poly-D-Lysine coated, glass slides with polystyrene vessel, lid and safety removal tool...
IMAGEQUANT 400 WKSTN, 1 EA. Category: ImageQuant CCD Imagers....
Biology Products: